AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03724773 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sugar-Tong Splint
Description: A sugar-tong splint is the application of hard splinting material on the front and back of the arm.
Study NCT01156792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP 100
Description: FP 100mcg BID
Study NCT01156792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP 100
Description: FP 100mcg BID
Study NCT01156792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 100
Description: GSK2190915 100mg QD (AM)
Study NCT01156792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 300
Description: GSK2190915 300mg QD (AM)
Study NCT01156792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: montelukast 10mg QD (PM)
Study NCT01156792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo BID
Study NCT01156792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP/SAL 100/50
Description: FP/SAL 100/50mcg BID
Study NCT02234687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomaglumetad Methionil 160mg
Description: Pomaglumetad Methionil 160mg, one dose, one time
Study NCT02234687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomaglumetad Methionil 40mg
Description: Pomaglumetad Methionil 40mg, one dose, one time
Study NCT02234687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, one dose, one time
Study NCT03663491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal Gastroscopy
Description: Use of transnasal endoscopes for routine gastroscopy in adults.
Study NCT03663491 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral Gastroscopy, unsedated
Description: Use of transoral endoscopes for routine gastroscopy in adults. Use of local anesthesia.
Study NCT03663491 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral Gastroscopy, sedated
Description: Use of transoral endoscopes for routine gastroscopy in adults. Use of intravenous sedation.
Study NCT03663491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Gastroscopy with transnasal endoscope, sedated
Description: Use of transnasal endoscopes for routine gastroscopy in adults, following a failed attempt to perform transnasal gastroscopy
Study NCT00965666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: All qualified subjects receive 24 weekly subcutaneous injections of Etanercept.
Study NCT04087980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Poseidon System
Description: Multicenter Pilot Study of the Poseidon System for the Ablation of Prostate Tissue Utilizing Sterile Water Vapor in Patients with Intermediate Risk Localized Prostate Cancer
Study NCT03700801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple combination therapy group
Description: Triple oral hypoglycemic therapy based on metformin, dapagliflozin plus saxagliptin.
Study NCT03700801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premixed insulin therapy group
Description: Subcutaneous injection therapy with insulin aspart 30 in patients with T2DM
Study NCT00117637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Multi kinase inhibitor
Study NCT00117637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon
Description: Interferon
Study NCT02417883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Evaluate urinary excretion rate fo furosemide
Study NCT01476007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral Cobalamin (vitamin B12)
Description: Intervention group: oral Optovite® B12 1000 gammas.
Study NCT01476007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intramuscular Cobalamin (vitamin B12)
Description: Control group: intramuscular Optovite® B12 1000 gammas.
Study NCT00474955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms or 135 micrograms sc weekly for 48 weeks
Study NCT00556907 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Intraoperative radiotherapy
Description: 20Gy to surface of tumor bed and 5Gy at depth of 1cm from surface of tumor bed
Study NCT00556907 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intraoperative radiotherapy
Description: 20gy to tumor bed, 5gy at depth of 1cm from surface of tumor bed
Study NCT01881516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: once per week for 6 weeks，30 mins for each treatment and for seven main acupoints
Study NCT01881516 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: the same acupoints and time as in acupuncture arm, but use a Park Sham Device
Study NCT03016572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Follow-Up Calls, Questionnaires
Study NCT03016572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crisis Intervention
Description: Frontline Services will be administering follow up phone calls for participants of the study, recently discharged from the emergency room.
Study NCT03016572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wraparound Services
Description: Tapestry will be assigning case management services for participants randomized into the third arm of the study.
Study NCT03767946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantiferon Gold Plus Test
Description: Small volume of whole blood incubated with specific TB antigen and then dosage of Interferon gamma production.
Study NCT03398213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture
Study NCT03398213 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Ear stimulation with plaster
Study NCT00057629 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure (PE)
Description: Prolonged Exposure (PE) consists of 10 weekly 90-minute treatment sessions, which may be extended up to 20 sessions, depending on client response. Treatment procedures include education about common reactions to trauma, breathing retraining, prolonged (repeated) exposure to trauma memories, repeated in vivo exposure to situations the client is avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises as well as beliefs about self and the world.
Study NCT02534493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carpal Tunnel Tissue Manipulation Device (CTMD)
Description: This piece of rigid, shaped, biocompatible plastic (polypropylene) rated for skin contact and a strong but safe hypoallergenic biocompatible medical adhesive which bonds the skin over the carpal tunnel to the plastic piece for a duration of 2-14 hours.
Study NCT04318561 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gallium-68 NODAGA-LM3 PET/CT
Description: Twenty patients will take this intervention. They will be further divided into two sub-groups with the same interventional radiopharmaceutical (Gallium-68 NODAGA-LM3) but different scanning protocols (Protocol A and Protocol B). The first enrolled 8 patients will go with Protocol A, who will undergo serial whole-body PET/CT scans at multiple time points (5m, 10m, 20m, 40m, 1h, 2h) after administering 40ug/150-200MBq Gallium-68 NODAGA-LM3. Baseline safety assessment will be conducted right before the study. The following 12 patients will go with Protocol B, who will undergo a whole-body PET/CT scan at 1 hour after administering 40ug/150-200MBq Gallium-68 NODAGA-LM3.
Study NCT04318561 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gallium-68 DOTA-LM3 PET/CT
Description: Twenty patients will take this intervention. They will be further divided into two sub-groups with the same intervention radiopharmaceutical (Gallium-68 DOTA-LM3) but different scanning protocols (Protocol C and Protocol D). The first enrolled 8 patients will go with Protocol C, who will undergo serial whole-body PET/CT scans at multiple time points (5m, 10m, 20m, 40m, 1h, 2h) after administering 40ug/150-200MBq Gallium-68 DOTA-LM3. Baseline safety assessment will be conducted right before the study. The following 12 patients will go with Protocol D, who will undergo a whole-body PET/CT scan at 1 hour after administering 40ug/150-200MBq Gallium-68 DOTA-LM3.
Study NCT04318561 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gallium-68 DOTATATE PET/CT
Description: All patients have to do a Gallium-68 DOTATATE PET/CT scan (40ug/150-200MBq, 1h post-injection) for comparison on the next day of LM3 scan. Safety assessment and tolerability of the previous LM3 study will be conducted right before the study.
Study NCT00057629 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual group therapy (TUGT)
Description: TUGT is delivered in ten weekly sessions, with 5 to 7 members and two counselors per group. There is not a formal, structured format for these groups; the counselors are sensitive to the participants' needs and follow their lead in terms of content covered in discussions and exercises. TUGT is conceptualized as supportive counseling and is based on the idea that members gain social support and information from one another.
Study NCT00057629 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive counseling (SC)
Description: Supportive counseling is an individual therapy delivered in 10 weekly, 90 minute sessions. During this treatment, the therapist helps the patient identify daily stresses that may or may not be related to traumatic events and discusses them in a supportive non-directive mode with a problem-solving orientation. The therapist uses active listening, encouragement of expression of feelings, praise, and encouragement. The goal of this present-focused treatment is to provide support and to help the client to identify problems and stresses of daily living and to help her cope with these. No instructions for exposure are given.
Study NCT00613665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: helicobacter pylori vaccine
Description: Experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly
Study NCT00613665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: helicobacter pylori vaccine
Description: Seven subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly
Study NCT00613665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: helicobacter pylori vaccine
Description: Seven subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,4 month schedule (alum control was administered at 2 months), administered intramuscularly
Study NCT00613665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: helicobacter pylori vaccine
Description: Eight subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,4 month schedule (alum control was administered at 2 months), administered intramuscularly
Study NCT00613665 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nine subjects, alum control (placebo comparator), 0,1,2,4 month schedule (served as control for arms 1-4), administered intramuscularly
Study NCT00613665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: helicobacter pylori vaccine
Description: Nine subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 week schedule, administered intramuscularly
Study NCT00613665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: helicobacter pylori vaccine
Description: Ten subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,2 week schedule, administered intramuscularly
Study NCT02849522 — intervention group
Intervention type: PROCEDURE
Intervention: Prostatic Artery Embolisation
Description: The aim of PAE for LUTS (due to BPH) is to reduce the blood supply of the prostate gland, causing some of it to undergo necrosis with subsequent shrinkage.~The procedure is usually performed with the patient under local anaesthetic and sedation. Using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation involves the introduction of microparticles to block these small prostatic arteries. Embolisation agents include polyvinyl alcohol (PVA), gelatine sponge and other synthetic biocompatible materials.~NICE published Interventional Procedures Guidance (IPG453) in April 2013. The evidence at the time of assessment was deemed inadequate in quantity and quality. Therefore, the procedure was given a 'Research-only' recommendation.
Study NCT02849522 — intervention group
Intervention type: PROCEDURE
Intervention: TURP
Description: Transurethral resection of the prostate. A cystoscope is passed up the urethra to the prostate, where the surrounding prostate tissue is excised. This is a common operation for benign prostatic hyperplasia (BPH), with around 15,000 procedures performed in the UK per year (NHS Choices). The conventional TURP method of tissue removal utilizes a wire loop with electrical current flowing in one direction (monopolar) through the resectoscope to cut the tissue. Bipolar TURP allows saline irrigation and eliminates the need for an ESU grounding pad thus preventing TUR syndrome and reducing other complications.
Study NCT02849522 — intervention group
Intervention type: PROCEDURE
Intervention: Open prostatectomy
Description: In an open prostatectomy the prostate is accessed through an incision that allows manual manipulation and open visualization through the incision. The most common types of open prostatectomy are retropubic prostatectomy (RP) or transvesical prostatectomy (TVP).
Study NCT02849522 — intervention group
Intervention type: PROCEDURE
Intervention: Laser prostate surgery
Description: This surgical method (HoLEP or KTP/Greenlight) utilizes laser energy to remove tissue. With laser prostate surgery a laser fibre inserted via an endoscope is used to transmit laser energy to enucleate (HoLEP) or vaporise (KTP) the tissue. The specific advantages of utilizing laser energy rather than a traditional electrosurgical TURP is a decrease in the relative blood loss, elimination of the risk of TUR syndrome, the ability to treat larger glands, as well as treating patients who are actively being treated with anti-coagulation therapy for unrelated diagnoses.
Study NCT03212989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Participants meeting criteria for Step 1 (exhibit ex-vivo response to VOR) will progress to Step 2 where they will receive a single dose of VOR 400 mg followed by a leukapheresis. If an increase in cell-associated HIV RNA (ca-RNA) is observed in-vivo following the single VOR dose, they will be eligible to donate cells for the manufacture of HXTC (Step 3). Successful manufacturing of the HIV-1 antigen expanded specific T cells will progress participants to combination treatment in Steps 4 and 5. In Steps 4 and Step 5, participants will receive two series of VOR dosing and HXTC infusions, for a total 20 doses of VOR 400 mg and 5 HXTC infusions.
Study NCT03212989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HXTC
Description: Participants meeting criteria for Step 1 (exhibit ex-vivo response to VOR) will progress to Step 2 where they will receive a single dose of VOR 400 mg followed by a leukapheresis. If an increase in cell-associated HIV RNA (ca-RNA) is observed in-vivo following the single VOR dose, they will be eligible to donate cells for the manufacture of HXTC (Step 3). Successful manufacturing of the HIV-1 antigen expanded specific T cells will progress participants to combination treatment in Steps 4 and 5. In Steps 4 and Step 5, participants will receive two series of VOR dosing and HXTC infusions, for a total 20 doses of VOR 400 mg and 5 HXTC infusions.
Study NCT01870908 — intervention group
Intervention type: DRUG
Intervention: tacrolimus
Study NCT01870908 — intervention group
Intervention type: DRUG
Intervention: biological agents
Study NCT00201227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: practice guideline adherence
Description: Project facilitator assist primary care practice clinicians and staff work in effective quality improvement teams through the use of facilitated collaborative meetings.
Study NCT01659788 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 concomitant treatment
Study NCT01659788 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03888989 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Quadrivalent inactivated influenza vaccine (IIV)
Description: Quadrivalent inactivated influenza vaccine (IIV), Intramuscular Injection
Study NCT02319759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: In the guselkumab group, Guselkumab 100 mg subcutaneous injection will be administered at Weeks 0, 4, 12, 20, 28, 36 and 44. In the placebo group, guselkumab 100 mg subcutaneous injection will be administered at Weeks 24, 28, 36 and 44 for participants remaining on placebo at Week 24.
Study NCT02319759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: In both placebo and guselkumab groups, if the participants qualify for early escape, they will switch to receive ustekinumab 45 mg or 90 mg subcutaneous injection at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
Study NCT02319759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In placebo group, Placebo subcutaneous injection will be administered at Weeks 0, 4, 12, and 20. In guselkumab group, placebo subcutaneous injection will be administered at Week 24 to maintain the blind.
Study NCT01659853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47 gel 0.5%/CD07805/47 Vehicle
Description: To maintain masking, CD07805/47 gel 0.5% will be administered along with CD07805/47 gel vehicle.~During each treatment period (baseline to Day 15):~CD07805/47 gel 0.5%, topical, once daily and CD07805/47 gel vehicle, topical, once daily
Study NCT01659853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelaic acid gel 15%
Description: During each treatment period (baseline to Day 15): azelaic acid gel 15%, topical, twice daily
Study NCT01611805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786
Description: Opaque Swedish orange body and cap.
Study NCT01611805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1605786 Placebo
Description: Opaque Swedish orange body and cap.
Study NCT03421626 — intervention group
Intervention type: DEVICE
Intervention: Xpert BCR-ABL Ultra
Description: Semi-quantitation of BCR-ABL transcript in patients that have been previously diagnosed with CML
Study NCT01085968 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PC based training
Description: Subjects sit at a computer and type a string of numbers that appears on the screen. As performance improves (# correct), the strings of numbers get longer. They are then instructed to repeat the string from memory. Performing these key entries from memory is a test of internally generated movement initiation.
Study NCT01085968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PC based training
Description: Subjects sit at a computer and type a string of numbers that appears on the screen. As performance improves (# correct), the strings of numbers get longer. They are then instructed to repeat the string from memory. Performing these key entries from memory is a test of internally generated movement initiation.
Study NCT00628004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biatain Ibu
Description: Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.
Study NCT00628004 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Local best practice
Description: N/A - since intervention is local best practice
Study NCT02907645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Local educational information
Description: Adult patients in this arm receive educational information regarding influenza vaccination based on local data
Study NCT02907645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: National educational information
Description: Adult patients in this arm receive educational information regarding influenza vaccination based on national data
Study NCT00952120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GSUC
Description: Gauze-based wall suction negative pressure wound therapy
Study NCT00952120 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VAC
Description: Commercially available Wound VAC negative pressure wound therapy device (KCI, Inc.)
Study NCT04541498 — intervention group
Intervention type: OTHER
Intervention: Impact of air pollution and climate changes
Description: To assess the short- and long- term impact of air pollution and climate changes
Study NCT00767975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid , randomized, open label
Description: isoniazid 300mg/tab 1 tab qd, 6 months (the other treatment arm is rifampin)